[LONDON, UK, 12th March 2024] Life Science Newswire – Specialist Biometrics CRO, Veramed, today announced the appointment of Karen Curran as Chief Strategy Officer at Veramed. Karen joins during a period of substantial global growth for the company.

With over 25 years in the industry, Karen brings a wealth of experience to her new role. As Chief Strategy Officer, she will work closely with pharmaceutical and biotech companies to establish innovative data management, statistics, and statistical programming partnerships.

Karen is recognized as an industry leader, known for her ability to develop and expand pharmaceutical services businesses globally. Her deep market knowledge enables her to provide strategic guidance and devise inventive solutions for biometric processes, including CDISC adoption and implementation, across large and small pharma and CRO environments. She has a track record of supporting successful submissions to regulatory bodies such as the FDA, EMEA, and the PMDA. Karen actively contributes to the PHUSE organization and currently serves on the CDISC Board of Directors.

“I’m thrilled to have joined Veramed at such an exciting stage of growth,” said Karen. “I look forward to collaborating with our clients and partners to pioneer innovative solutions that meet both short and long-term goals, leading to more efficient and meaningful partnership models.”

Matt Jones, Co-Founder and CEO of Veramed, expressed his enthusiasm about Karen joining the team: "We're excited to have Karen on board as Chief Strategy Officer as we solidify our position as the industry’s CRO of choice."

Veramed continues to excel in delivering exceptional biometrics services worldwide, and Karen's appointment underscores the company’s commitment to driving innovation and meeting the evolving needs of the biopharmaceutical industry.

About Veramed

Veramed is a high-performing partner for the whole biometrics value chain, including statistical consultancy, data management, FSP services, clinical trial reporting and automation, DMC, and evidence and value generation. It was awarded “Best Contract Research Organization – Specialist Providers” at the 18th Annual Scrip Awards in 2022 and certified as a B Corp for the first time in 2020.

The company is a pioneering CRO that is redefining intelligent healthcare decision-making. The talented Veramed team is paving the way for pharma and biotech clients by offering tailored biometrics solutions that scale and adapt as needs grow. This takes various forms; from getting the basics of study design and analysis of clinical trials right, to Automation on sponsor systems, Real World Evidence, visualizations using R, and industry-leading involvement in Dataset J-SON and the OpenSource OAK project. The company works hard to customize solutions and adapt to client needs, whilst always staying true to the founding culture of promoting work-life balance for their staff and happiness within the workplace.

Veramed is a certified B Corp and is passionate about making a difference in patient communities around the world. Being uniquely practitioner-led, the company challenges how advanced biometrics services can be used to help move the needle on the speed, quality, and effectiveness of pharma and biotech pipeline delivery.